The registration program for ONC201 focuses on patients with brain tumors that contain the H3 K27M mutation based on durable objective responses in the recurrent setting. The ACTION study is a randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating ONC201 in patients with ne...
Evaluation of the biomarker signature across tumor types and patient-derived tissue microarrays revealed enrichment of tumor types associated with ONC201 clinical activity including high-grade glioma, endometrial cancer and adrenal tumors. However, these biomarker relationships continue to be studied in ...
phase 2 clinical trialsfacial nerve diseasesgliomaONC201, an anti-cancer DRD2 antagonist and ClpP agonist, is in Phase II trials for adult H3 K27M-mutant diffuse midline gliomas. The recommended phase 2 dose (RP2D) of 625mg ONC201 once a week has been established as a biologically active ...
TIC10(Synonyms: ONC-201)纯度: 99.80% TIC10 (ONC-201) 是一种有效,有口服活性,稳定的肿瘤坏死因子相关的凋亡诱导配体TRAIL诱导剂,其通过抑制Akt和ERK起作用,从而激活 Foxo3a 并显着诱导细胞表面 TRAIL。TIC10 可透过血脑屏障。 TIC10Chemical Structure CAS No. :1616632-77-9 *Please selectQuantitybefore a...
ONC201 is scheduled to enter Phase I/II clinical trials as a monoagent for advanced cancers in adults in 2014. We have previously shown that ONC201 induces significant cytotoxicity in preclinical models of human lymphomas (Talekar et al, ASPHO 2014). Here, we show that ONC201 is not only...
Conclusion While the efficacy of ONC201 needs validation in a controlled randomized clinical trial, our real-life data support a better outcome for patients with thalamic tumors treated with ONC201. We demonstrated furthermore the feasibility of a successful academia-driven compassionate use programPrevi...
First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors. Clin. Cancer Res. 2017, 23, 4163–4169. [Google Scholar] [CrossRef] Arrillaga-Romany, I.; Chi, A.S.; Allen, J.E.; Oster, W.; Wen, P.Y.; Batchelor, T.T. A phase 2 study of the first ...
AGAVE-201 Trial Review Corey S. Cutler, MD, MPH, FRCPC;Hannah Choe, MD July 13th 2024 A hematologist provides an overview of the AGAVE-201 trial investigating axatilimab in patients with chronic graft-vs-host disease. Watch FDA Wraps Up End Of Phase 2 Meeting for AML Combination Therapy ...
Axatilimab demonstrated consistent response and durability in chronic graft-versus-host disease, regardless of prior treatments, in a phase 1 AGAVE-201 trial analysis. Read More FDA Approves Brentuximab Vedotin Triplet in R/R Large B-cell Lymphoma ...
We previously identified ONC201 (TIC10) as a first-in-class orally active small molecule with robust antitumor activity that is currently in clinical trial... Joshua,E,Allen,... - 《Plos One》 被引量: 24发表: 2015年 Abstract 4604: Imipridones ONC201 and ONC212 exhibit anti-tumor activit...